Claire N Harrison

List of Publications by Year
in descending order

181	13,756	36303 51	22166 113
papers	citations	h-index	g-index

185	185	185	8160
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis. New England Journal of Medicine, 2012, 366, 787-798.	27.0	1,543
2	JAK2Exon 12 Mutations in Polycythemia Vera and Idiopathic Erythrocytosis. New England Journal of Medicine, 2007, 356, 459-468.	27.0	1,173
3	Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet. Journal of Clinical Oncology, 2011, 29, 761-770.	1.6	724
4	Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera. New England Journal of Medicine, 2015, 372, 426-435.	27.0	720
5	Effect of Mutation Order on Myeloproliferative Neoplasms. New England Journal of Medicine, 2015, 372, 601-612.	27.0	467
6	Classification and Personalized Prognosis in Myeloproliferative Neoplasms. New England Journal of Medicine, 2018, 379, 1416-1430.	27.0	442
7	Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia, 2018, 32, 1057-1069.	7.2	415
8	Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis. JAMA Oncology, 2015, 1, 643.	7.1	362
9	Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs. Journal of Clinical Oncology, 2012, 30, 4098-4103.	1.6	344
10	Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. British Journal of Haematology, 2005, 130, 174-195.	2.5	314
11	Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood, 2013, 122, 1395-1398.	1.4	286
12	The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients. Blood, 2011, 118, 401-408.	1.4	280
13	Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis. JAMA Oncology, 2018, 4, 652.	7.1	261
14	Guideline for investigation and management of adults and children presenting with a thrombocytosis. British Journal of Haematology, 2010, 149, 352-375.	2.5	253
15	Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. Lancet Haematology,the, 2017, 4, e317-e324.	4.6	243
16	Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. Blood, 2008, 111, 60-70.	1.4	229
17	Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial. Lancet Haematology,the, 2017, 4, e225-e236.	4.6	224
18	Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood, 2013, 121, 4778-4781.	1.4	219

#	Article	IF	Citations
19	Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. Lancet Haematology,the, 2018, 5, e73-e81.	4.6	211
20	Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. Journal of Hematology and Oncology, 2017, 10, 156.	17.0	210
21	The Myelofibrosis Symptom Assessment Form (MFSAF): An evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leukemia Research, 2009, 33, 1199-1203.	0.8	203
22	A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica, 2015, 100, 1139-1145.	3.5	203
23	Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms. Nature Communications, 2015, 6, 6691.	12.8	145
24	A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. British Journal of Haematology, 2010, 148, 961-963.	2.5	144
25	Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. Haematologica, 2016, 101, 821-829.	3.5	140
26	Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide. Blood, 2017, 130, 1889-1897.	1.4	130
27	Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation. Haematologica, 2016, 101, 926-931.	3.5	118
28	Current and future status of JAK inhibitors. Lancet, The, 2021, 398, 803-816.	13.7	117
29	Pregnancy and its management in the Philadelphia negative myeloproliferative diseases. British Journal of Haematology, 2005, 129, 293-306.	2.5	111
30	A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline. British Journal of Haematology, 2019, 184, 176-191.	2.5	102
31	Amendment to the guideline for diagnosis and investigation of polycythaemia/erythrocytosis. British Journal of Haematology, 2007, 138, 821-822.	2.5	99
32	Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the <scp>JAKARTA2</scp> study using stringent criteria for ruxolitinib failure. American Journal of Hematology, 2020, 95, 594-603.	4.1	96
33	The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey. Annals of Hematology, 2017, 96, 1653-1665.	1.8	92
34	Guideline for the diagnosis and management of myelofibrosis. British Journal of Haematology, 2012, 158, 453-471.	2.5	89
35	Molecular diagnosis of the myeloproliferative neoplasms: <scp>UK</scp> guidelines for the detection of <scp>JAK</scp>2 <scp>V</scp>617<scp>F</scp> and other relevant mutations. British Journal of Haematology, 2013, 160, 25-34.	2.5	87
36	Immunological Consequences of JAK Inhibition: Friend or Foe?. Current Hematologic Malignancy Reports, 2015, 10, 370-379.	2.3	84

#	Article	IF	Citations
37	Essential thrombocythaemia: challenges and evidence-based management. British Journal of Haematology, 2005, 130, 153-165.	2.5	79
38	Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients. Blood, 2014, 123, 3803-3810.	1.4	79
39	A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis. British Journal of Haematology, 2019, 184, 161-175.	2.5	76
40	Healthâ€related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. British Journal of Haematology, 2013, 162, 229-239.	2.5	75
41	<scp>JAK</scp> inhibition induces silencing of T Helper cytokine secretion and a profound reduction in T regulatory cells. British Journal of Haematology, 2015, 171, 60-73.	2.5	73
42	High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib. Leukemia, 2021, 35, 485-493.	7.2	70
43	A phase II study of vorinostat (<scp>MK</scp>â€0683) in patients with polycythaemia vera and essential thrombocythaemia. British Journal of Haematology, 2013, 162, 498-508.	2.5	65
44	Pregnancy outcomes in myeloproliferative neoplasms: <scp>UK</scp> prospective cohort study. British Journal of Haematology, 2016, 175, 31-36.	2.5	65
45	Management of myelofibrosis after ruxolitinib failure. Annals of Hematology, 2020, 99, 1177-1191.	1.8	62
46	Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy. Journal of Clinical Oncology, 2022, 40, 1671-1680.	1.6	60
47	Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study. Haematologica, 2018, 103, 51-60.	3.5	58
48	Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease. Journal of Clinical Oncology, 2016, 34, 151-159.	1.6	56
49	State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019. Haematologica, 2019, 104, 659-668.	3.5	56
50	Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirusâ€2 (SARSâ€CoVâ€2) induces neutralising antibody and polyfunctional Tâ€cell responses in patients with chronic myeloid leukaemia. British Journal of Haematology, 2021, 194, 999-1006.	2.5	55
51	Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features. Journal of Clinical Oncology, 2018, 36, 3361-3369.	1.6	54
52	A Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia. Blood, 2019, 134, 557-557.	1.4	54
53	Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases. American Journal of Hematology, 2020, 95, 156-166.	4.1	53
54	Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians. Therapeutic Advances in Hematology, 2012, 3, 341-354.	2.5	50

#	Article	IF	Citations
55	The management and outcome of 18 pregnancies in women with polycythemia vera. Haematologica, 2005, 90, 1477-83.	3.5	49
56	Pegylated interferon alpha-2a for essential thrombocythemia during pregnancy: outcome and safety. A case series. Haematologica, 2016, 101, e182-e184.	3.5	47
57	Current trends in essential thrombocythaemia. British Journal of Haematology, 2002, 117, 796-808.	2.5	46
58	Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations. Lancet Haematology,the, 2022, 9, e301-e311.	4.6	46
59	Characteristics and outcomes of patients with essential thrombocythemia or polycythemia vera diagnosed before 20 years of age: a systematic review. Haematologica, 2019, 104, 1580-1588.	3.5	42
60	MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), As Monotherapy or "Add-on" to Ruxolitinib, in Patients with Refractory or Intolerant Advanced Myelofibrosis. Blood, 2019, 134, 670-670.	1.4	42
61	Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms. Leukemia, 2021, 35, 3573-3577.	7.2	41
62	Modification of British Committee for Standards in Haematology diagnostic criteria for essential thrombocythaemia. British Journal of Haematology, 2014, 167, 421-423.	2.5	40
63	Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 Randomized Trial of Pegylated Interferon Alfa-2a (PEG) Versus Hydroxyurea (HU) Therapy for the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET). Blood, 2018, 132, 577-577.	1.4	39
64	Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. Haematologica, 2014, 99, 292-298.	3.5	38
65	Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent CSF3R mutations in chronic neutrophilic leukemia. Haematologica, 2017, 102, e238-e240.	3.5	38
66	Use of <scp>JAK</scp> inhibitors in the management of myelofibrosis: a revision of the <scp>B</scp>ritish <scp>C</scp>ommittee for <scp>S</scp>tandards in <scp>H</scp>aematology <scp>G</scp>uidelines for <scp>I</scp>nvestigation and <scp>M</scp>anagement of <scp>M</scp>yelofibrosis 2012. British Journal of Haematology, 2014, 167, 418-420.	2.5	37
67	Updated results of the placeboâ€controlled, phase III JAKARTA trial of fedratinib in patients with intermediateâ€2 or highâ€risk myelofibrosis. British Journal of Haematology, 2021, 195, 244-248.	2.5	37
68	Results from a Phase 2 Study of Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary Myelofibrosis. Blood, 2019, 134, 671-671.	1.4	36
69	Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients. Leukemia, 2021, 35, 2989-2993.	7.2	34
70	EXPAND, a dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts: 48-week follow-up analysis. Haematologica, 2019, 104, 947-954.	3.5	33
71	How we manage Philadelphiaâ€negative myeloproliferative neoplasms in pregnancy. British Journal of Haematology, 2020, 189, 625-634.	2.5	33
72	Interim Analysis of the Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia. Blood, 2016, 128, 479-479.	1.4	32

#	Article	IF	Citations
73	Managing hematological cancer patients during the COVID-19 pandemic: anÂESMO-EHA Interdisciplinary Expert Consensus. ESMO Open, 2022, 7, 100403.	4.5	32
74	Practical management of patients with myelofibrosis receiving ruxolitinib. Expert Review of Hematology, 2013, 6, 511-523.	2.2	31
75	MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic. Future Oncology, 2021, 17, 1449-1458.	2.4	31
76	Essential thrombocythemia. Hematology/Oncology Clinics of North America, 2003, 17, 1175-1190.	2.2	29
77	Cytoreductive treatment patterns for essential thrombocythemia in Europe. Analysis of 3643 patients in the EXELS study. Leukemia Research, 2013, 37, 162-168.	0.8	29
78	Managing side effects of JAK inhibitors for myelofibrosis in clinical practice. Expert Review of Hematology, 2017, 10, 617-625.	2.2	29
79	Treatment of thromboembolic events coincident with the diagnosis of myeloproliferative neoplasms: A physician survey. Thrombosis Research, 2014, 134, 251-254.	1.7	28
80	Management of polycythaemia vera: a critical review of current data. British Journal of Haematology, 2016, 172, 337-349.	2.5	28
81	Myeloproliferative Disorders in Pregnancy. Hematology/Oncology Clinics of North America, 2011, 25, 261-275.	2.2	25
82	Safety evaluation of ruxolitinib for treating myelofibrosis. Expert Opinion on Drug Safety, 2014, 13, 967-976.	2.4	25
83	Outcomes of patients receiving direct oral anticoagulants for myeloproliferative neoplasmâ€associated venous thromboembolism in a large tertiary centre in the UK. British Journal of Haematology, 2020, 189, e79-e81.	2.5	24
84	Phase 1b/2 Study of the Efficacy and Safety of Sonidegib (LDE225) in Combination with Ruxolitinib (INC424) in Patients with Myelofibrosis. Blood, 2015, 126, 825-825.	1.4	24
85	Markers of iron deficiency in patients with polycythemia vera receiving ruxolitinib or best available therapy. Leukemia Research, 2017, 56, 52-59.	0.8	22
86	Preliminary Report of MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), in Combination with Ruxolitinib, in JAK Inhibitor (JAKi) Treatment NaÃ¯ve Myelofibrosis Patients. Blood, 2019, 134, 4164-4164.	1.4	21
87	The Addition of Navitoclax to Ruxolitinib Demonstrates Efficacy within Different High-Risk Populations in Patients with Relapsed/Refractory Myelofibrosis. Blood, 2020, 136, 49-50.	1.4	21
88	How we diagnose and treat essential thrombocythaemia. British Journal of Haematology, 2015, 171, 306-321.	2.5	20
89	Bone marrow niche dysregulation in myeloproliferative neoplasms. Haematologica, 2020, 105, 1189-1200.	3.5	20
90	Real-world survival of US patients with intermediate- to high-risk myelofibrosis: impact of ruxolitinib approval. Annals of Hematology, 2022, 101, 131-137.	1.8	20

#	Article	IF	Citations
91	Rethinking Disease Definitions and Therapeutic Strategies in Essential Thrombocythemia and Polycythemia Vera. Hematology American Society of Hematology Education Program, 2010, 2010, 129-134.	2.5	19
92	<scp>J</scp>anus kinase Inhibition and its effect upon the therapeutic landscape for myelofibrosis: from palliation to cure?. British Journal of Haematology, 2012, 157, 426-437.	2.5	19
93	The use of JAK inhibitors for low-risk myelofibrosis. Expert Review of Hematology, 2015, 8, 551-553.	2.2	19
94	What is preâ€fibrotic myelofibrosis and how should it be managed in 2018?. British Journal of Haematology, 2018, 183, 23-34.	2.5	18
95	Realâ€world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study. British Journal of Haematology, 2021, 192, 62-74.	2.5	18
96	Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinaseâ€2 (<scp>JAK2</scp>), in patients with myelofibrosis and low pretreatment platelet counts. British Journal of Haematology, 2022, 198, 317-327.	2.5	18
97	Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study. Lancet Haematology,the, 2022, 9, e434-e444.	4.6	18
98	Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet. Lancet Haematology,the, 2021, 8, e658-e665.	4.6	17
99	MANIFEST-2, a Global, Phase 3, Randomized, Double-Blind, Active-Control Study of CPI-0610 and Ruxolitinib Vs. Placebo and Ruxolitinib in JAK-Inhibitor-Naive Myelofibrosis Patients. Blood, 2020, 136, 43-43.	1.4	17
100	Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidence. Leukemia and Lymphoma, 2016, 57, 2259-2267.	1.3	16
101	Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study design. Future Oncology, 2022, 18, 2393-2402.	2.4	14
102	Aspirin in low-risk essential thrombocythemia, not so simple after all?. Leukemia Research, 2011, 35, 286-289.	0.8	13
103	Evidence of robust memory Tâ€cell responses in patients with chronic myeloproliferative neoplasms following infection with severe acute respiratory syndrome coronavirusâ€2 (SARSâ€CoVâ€2). British Journal of Haematology, 2021, 193, 692-696.	2.5	13
104	Targeting of the Hedgehog pathway in myeloid malignancies: still a worthy chase?. British Journal of Haematology, 2015, 170, 323-335.	2.5	12
105	The poor outcome in high molecular risk, hydroxycarbamide-resistant/intolerant ET is not ameliorated by ruxolitinib. Blood, 2019, 134, 2107-2111.	1.4	12
106	Depressive symptoms and myeloproliferative neoplasms: Understanding the confounding factor in a complex condition. Cancer Medicine, 2020, 9, 8301-8309.	2.8	12
107	Current and future therapies for myelofibrosis. Blood Reviews, 2020, 42, 100715.	5.7	12
108	The Addition of Gemtuzumab Ozogamicin to Intensive Chemotherapy in Older Patients with AML Produces a Significant Improvement in Overall Survival: Results of the UK NCRI AML16 Randomized Trial. Blood, 2011, 118, 582-582.	1.4	12

#	Article	IF	Citations
109	How We Identify and Manage Patients with Inadequately Controlled Polycythemia Vera. Current Hematologic Malignancy Reports, 2016, 11, 356-367.	2.3	11
110	An updated review of the JAK1/2 inhibitor (ruxolitinib) in the Philadelphia-negative myeloproliferative neoplasms. Future Oncology, 2018, 14, 137-150.	2.4	11
111	Ruxolitinib for the Treatment of Essential Thrombocythemia. HemaSphere, 2018, 2, e56.	2.7	11
112	ImmunoCluster provides a computational framework for the nonspecialist to profile high-dimensional cytometry data. ELife, 2021, 10, .	6.0	11
113	JAK inhibitors and myelofibrosis, Einstein and ruxolitinib. Haematologica, 2015, 100, 409-411.	3.5	10
114	Facing erythrocytosis: Results of an international physician survey. American Journal of Hematology, 2019, 94, E225-E227.	4.1	10
115	Current and future role of fedratinib in the treatment of myelofibrosis. Future Oncology, 2020, 16, 175-186.	2.4	10
116	Altered immune response to the annual influenza A vaccine in patients with myeloproliferative neoplasms. British Journal of Haematology, 2021, 193, 150-154.	2.5	10
117	Disease characteristics and outcomes in younger adults with primary and secondary myelofibrosis. British Journal of Haematology, 2016, 175, 37-42.	2.5	9
118	Clinicopathological characterisation of myeloproliferative neoplasmâ€unclassifiable (MPNâ€U): a retrospective analysis from a large UK tertiary referral centre. British Journal of Haematology, 2021, 193, 792-797.	2.5	9
119	Phazar: A Phase Ib Study to Assess the Safety and Tolerability of Ruxolitinib in Combination with Azacitidine in Advanced Phase Myeloproliferative Neoplasms (MPN), Including Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukaemia (AML) Arising from MPN [ISRCTN16783472]. Blood, 2020, 136, 2-3.	1.4	9
120	Safety and Tolerability of Fedratinib (FEDR), an Oral Inhibitor of Janus Kinase 2 (JAK2), in Patients with Intermediate- or High-Risk Myelofibrosis (MF) Previously Treated with Ruxolitinib (RUX): Results from the Phase 3b FREEDOM Trial. Blood, 2021, 138, 389-389.	1.4	9
121	Pacritinib: a new agent for the management of myelofibrosis?. Expert Opinion on Pharmacotherapy, 2015, 16, 2381-2390.	1.8	8
122	Reply to J. Thiele et al. Journal of Clinical Oncology, 2009, 27, e222-e223.	1.6	7
123	SOHO State-of-the-Art Update and Next Questions: MPN. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 1-12.	0.4	7
124	Exploitation of the neural-hematopoietic stem cell niche axis to treat myeloproliferative neoplasms. Haematologica, 2019, 104, 639-641.	3.5	7
125	Safety and efficacy of the combination of sonidegib and ruxolitinib in myelofibrosis: a phase 1b/2 dose-finding study. Blood Advances, 2020, 4, 3063-3071.	5.2	7
126	Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial. HemaSphere, 2021, 5, e553.	2.7	7

#	Article	IF	Citations
127	A Randomized, Phase 3 Trial of Fedratinib Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Previously Treated with Ruxolitinib (FREEDOM2). Blood, 2021, 138, 3643-3643.	1.4	7
128	<scp>Chronic myeloid leukaemia</scp> patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted Tâ€cell phenotype. British Journal of Haematology, 2022, 198, 1011-1015.	2.5	7
129	Essential thrombocythaemia treated with recombinant interferon: â€˜real world' United Kingdom referral centre experience. British Journal of Haematology, 2019, 186, 561-564.	2.5	6
130	<scp>UK</scp> results from the myeloproliferative neoplasms (<scp>MPN</scp>) landmark survey on the symptom, emotional and economic burden of <scp>MPN</scp>. British Journal of Haematology, 2019, 186, e1-e4.	2.5	6
131	Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial. Blood, 2018, 132, 3032-3032.	1.4	6
132	Real-World Survival Among Patients with Intermediate- to High-Risk Myelofibrosis in the United States: Impact of Ruxolitinib Approval. Blood, 2020, 136, 46-47.	1.4	6
133	Combination therapies in Myeloproliferative Neoplasms: why do we need them and how to identify potential winners?. Journal of Cellular and Molecular Medicine, 2013, 17, 1410-1414.	3.6	5
134	How many JAK inhibitors in myelofibrosis?. Best Practice and Research in Clinical Haematology, 2014, 27, 187-195.	1.7	5
135	Does Early Intervention in Myelofibrosis Impact Outcomes? a Pooled Analysis of the Comfort I and II Studies. Blood, 2021, 138, 1505-1505.	1.4	5
136	Anagrelide for control of thrombocytosis due to myeloproliferative disorders. Future Oncology, 2005, 1, 609-618.	2.4	4
137	Management of Essential Thrombocythemia: Implications of the Medical Research Council Primary Thrombocythemia 1 Trial. Seminars in Thrombosis and Hemostasis, 2006, 32, 283-288.	2.7	4
138	Clinical Significance of MPL Mutations in Essential Thrombocythemia: Analysis of the PT-1 Cohort.. Blood, 2007, 110, 677-677.	1.4	4
139	The Myleloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Derived Total Symptom Score (TSS): An International Trial of 1433 Patients with Myeloproliferative Neoplasms (MPNs),. Blood, 2011, 118, 3839-3839.	1.4	4
140	A Randomised Comparison of Clofarabine Versus Low Dose Ara-C As First Line Treatment for Older Patients with AML. Blood, 2012, 120, 889-889.	1.4	4
141	Symptom Burden As Primary Driver for Therapy in Patients with Myelofibrosis: An Analysis By MPN International Quality of Life Study Group. Blood, 2016, 128, 3117-3117.	1.4	4
142	Molecular Classification of Myeloproliferative Neoplasmsâ€"Pros and Cons. Current Hematologic Malignancy Reports, 2013, 8, 342-350.	2.3	3
143	Shortened telomeres in essential thrombocythemia: clinicopathological and treatment correlations. Haematologica, 2018, 103, e234-e236.	3.5	3
144	Comprehensive haematological control with ruxolitinib in patients with polycythaemia vera resistant to or intolerant of hydroxycarbamide. British Journal of Haematology, 2018, 182, 279-284.	2.5	3

#	Article	IF	Citations
145	Forging ahead or moving back: dilemmas and disappointments of novel agents for myeloproliferative neoplasms. British Journal of Haematology, 2020, 191, 21-36.	2.5	3
146	Hydroxycarbamide effects on DNA methylation and gene expression in myeloproliferative neoplasms. Genome Research, 2021, 31, 1381-1394.	5.5	3
147	A phase 1b, dose-finding study of ruxolitinib plus panobinostat in patients with myelofibrosis.. Journal of Clinical Oncology, 2014, 32, 7022-7022.	1.6	3
148	Natural History of Idiopathic Erythrocytosis â˜ A Retrospective Case Series Review.. Blood, 2006, 108, 1298-1298.	1.4	3
149	Management of myelofibrosis â€“ where next?. Expert Opinion on Pharmacotherapy, 2011, 12, 1453-1455.	1.8	2
150	Orphan drugs for myelofibrosis. Expert Opinion on Orphan Drugs, 2014, 2, 391-405.	0.8	2
151	Hb Baden: a rare high affinity haemoglobin variant and its management. Journal of Clinical Pathology, 2018, 71, 79-80.	2.0	2
152	Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF): Updated Results from the Randomized, Placebo-Controlled, Phase III JAKARTA Trial. Blood, 2020, 136, 10-12.	1.4	2
153	The BET Inhibitor, CPI-0610, Promotes Myeloid Differentiation in Myelofibrosis Patient Bone Marrow and Peripheral CD34+ Hematopoietic Stem Cells. Blood, 2020, 136, 37-38.	1.4	2
154	A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study. Therapeutic Advances in Hematology, 2022, 13, 204062072210844.	2.5	2
155	How I manage myeloproliferative neoplasmâ€unclassifiable: Practical approaches for 2022 and beyond. British Journal of Haematology, 2022, , .	2.5	2
156	Do we know more about essential thrombocythemia because of JAK2V617F?. Current Hematologic Malignancy Reports, 2009, 4, 25-32.	2.3	1
157	Polycythemia vera: can we do better?. Expert Opinion on Pharmacotherapy, 2013, 14, 687-689.	1.8	1
158	A physician survey on the application of the British Society for Haematology guidelines for the diagnosis and management of myelofibrosis in the UK. British Journal of Haematology, 2020, 188, e105-e109.	2.5	1
159	Large Scale Internet-based Survey of Patients With a Myeloproliferative Neoplasm: Opinions and Experiences Regarding SARS-CoV-2 (COVID-19) Vaccination Strategies in 2021. HemaSphere, 2021, 5, e609.	2.7	1
160	Results from the Myeloproliferative Neoplasm Patient Care Survey: Patient Care Opportunities and Challenges. Blood, 2018, 132, 4289-4289.	1.4	1
161	The Presence of the V617F Mutation Is Associated with Higher Haemoglobin, Older Age and an Increased Risk of Thrombosis in Essential Thrombocythemia.. Blood, 2005, 106, 3531-3531.	1.4	1
162	Myeloproliferative Disorders Are Associated with an Increase in Levels of Prothrombotic and Inflammatory Markers Despite Cytoreductive Therapy.. Blood, 2006, 108, 3625-3625.	1.4	1

#	Article	IF	Citations
163	A prospective registry-based cohort study of the diagnosis and management of acute leukaemia in pregnancy: Study protocol. PLoS ONE, 2022, 17, e0263195.	2.5	1
164	Clonality in essential thrombocythaemia. Laboratory Hematology: Official Publication of the International Society for Laboratory Hematology, 2004, 10, 184-7.	1.2	1
165	Diagnostic and management strategies for Myeloproliferative Neoplasm-Unclassifiable (MPN-U): An international survey of contemporary practice. Current Research in Translational Medicine, 2022, 70, 103338.	1.8	1
166	Abstract LB108: Addition of navitoclax to ruxolitinib mediates responses suggestive of disease modification in patients with myelofibrosis previously treated with ruxolitinib monotherapy. Cancer Research, 2022, 82, LB108-LB108.	0.9	1
167	Update in the myeloproliferative neoplasms. Clinical Medicine, 2014, 14, s66-s70.	1.9	0
168	Essential thrombocythaemia. Hematology, 2015, 20, 119-120.	1.5	0
169	How We Treat Myeloproliferative Neoplasms. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S19-S26.	0.4	0
170	Is there a role for pomalidomide in the treatment of myelofibrosis?. Expert Opinion on Orphan Drugs, 2016, 4, 501-509.	0.8	0
171	JAK inhibitors truly changing the therapeutic paradigm in myelofibrosis. Journal of Medical Economics, 2016, 19, 443-444.	2.1	0
172	A discussion of blood cancers and the MPN landmark survey. International Journal of Hematologic Oncology, 2017, 6, 101-104.	1.6	0
173	The Use of the PFA-100Â® and Thromboelastograph in Assessing Haemostasis and Drug Efficacy in Essential Thrombocythemia.. Blood, 2005, 106, 4959-4959.	1.4	0
174	Impact of Platelet Glycoprotein Polymorphisms upon Clinical Events in Essential Thrombocythaemia Patients Enrolled in the PT1 Trial.. Blood, 2007, 110, 2543-2543.	1.4	0
175	Longitudinal Mutational Analysis in Hydroxycarbamide-Resistant/Intolerant Essential Thrombocythemia Treated on the Majic-ET Study. Blood, 2018, 132, 1784-1784.	1.4	0
176	Myeloproliferative Neoplasms in Patients below 25 Years Old at Diagnosis: A Retrospective International Cooperative Work. Blood, 2018, 132, 1759-1759.	1.4	0
177	Immune Checkpoint Analysis of T Effectors and Regulatory T Cells in Patients with CML Reveals Increased Expression at Diagnosis and with Refractory Disease. Blood, 2021, 138, 2545-2545.	1.4	0
178	Spleen and Symptom Responses with Fedratinib (FEDR) in Patients with Myelofibrosis (MF) and Substantial Splenomegaly. Blood, 2021, 138, 2576-2576.	1.4	0
179	A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase (JAK) Inhibitor. Blood, 2020, 136, 43-44.	1.4	0
180	Mechanism of thrombosis in essential thrombocythaemia. Haematologica, 2006, 91, 145b.	3.5	0

#	Article	IF	Citations
181	A randomised comparison of <scp>FLAGâ€ida</scp> versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: Results from the <scp>UK NCRI AML17</scp> trial. British Journal of Haematology, 2022, , .	2.5	0